Table 1.

Adjudication Status of Newly Initiated Oral Oncolytic Claims

Patient Characteristic	Total		Adjudication Status
			Paid or Reversed With Follow-Up		Abandoned
	No.	%	No.	%	No.	%
Total patients	10,508	100.0	9,455	90.0	1,053	10.0
Age, years*
0-40	302	2.9	272	90.1	30	9.9
41-65	5,109	48.6	4,672	91.5	437	8.6
65-80	3,837	36.5	3,419	89.1	418	10.9
> 81	1,260	12.0	1,092	86.7	168	13.3
Sex
Female	5,548	52.8	5,009	90.3	539	9.7
Male	4,960	47.2	4,446	89.6	514	10.4
Annual household income*
< $40,000	2,721	25.9	2,410	88.6	311	11.4
$40,000-$75,000	4,038	38.4	3,626	89.8	412	10.2
> $75,000	3,749	35.7	3,419	91.2	330	8.8
Geographic region
Midwest	2,355	22.4	2,105	89.4	250	10.6
Northeast	2,764	26.3	2,479	89.7	285	10.3
South	3,692	35.1	3,343	90.6	349	9.5
West	1,697	16.1	1,528	90.0	169	10.0
Patient cost-sharing amount*
$0-$100	7,638	72.7	7,147	93.6	491	6.4
$101-$150	271	2.6	242	89.3	29	10.7
$151-$200	258	2.5	234	90.7	24	9.3
$201-$250	123	1.2	108	87.8	15	12.2
$251-$350	291	2.8	256	88.0	35	12.0
$351-$500	200	1.9	168	84.0	32	16.0
> $500	1,727	16.4	1,300	75.3	427	24.7
Insurance type*
Medicare	1,737	16.5	1,467	84.5	270	15.5
Commercial	8,771	83.5	7,988	91.1	783	8.9
Prescription activity, No. of claims*
0	3,049	29.0	2,775	91.0	274	9.0
1	1,318	12.5	1,207	91.6	111	8.4
2-3	2,168	20.6	1,947	89.8	221	10.2
4-5	1,550	14.8	1,383	89.2	167	10.8
> 5	2,423	23.1	2,143	88.4	280	11.6
Study drug*
Capecitabine	3,758	35.8	3,527	93.9	231	6.2
Imatinib	1,380	13.1	1,194	86.5	186	13.5
Sorafenib	460	4.4	335	72.8	125	27.2
Lenalidomide	1,038	9.9	960	92.5	78	7.5
Sunitinib	569	5.4	501	88.1	68	12.0
Erlotinib	2,022	19.2	1,763	87.2	259	12.8
Temozolomide	1,060	10.1	982	92.6	78	7.4
Lapatinib	221	2.1	193	87.3	28	12.7

^*χ²; P < .05.